Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis

Figures & data

Figure 1. Flow diagram depicting the selection of studies included in the meta-analysis.

Table I. Characteristics of randomized controlled trials included in the meta-analysis.

		Age, mean (SD),						Hypercholesterolemia,
		Patients, n		y		Male, n (%)		DM, n (%)		n (%)		GPI, n (%)
Author	Trial, published date	Statins	Control	Statins	Control	Statins	Control	Statins	Control	Statins	Control	Statins	Control	Primary end-point
Pasceri V, et al. (4)	ARMYDA, 2004	76	77	65 (10)	64 (10)	67 (87)	64 (82)	15 (19)	21 (27)	32 (42)	32 (41)	12 (16)	19 (25)	periprocedural myocardial infarction
Briguori C, et al. (5)	ARMYDA, 2004	226	225	63 (7)	62 (9)	194 (86)	197 (88)	57 (25)	43 (19)	NA	NA	104 (46)	122 (54)	large non-Q-wave myocardial infarction
Patti G, et al. (6)	ARMYDA-ACS, 2007	86	85	64 (11)	67 (10)	68 (79)	67 (79)	25 (29)	28 (33)	27 (31)	28 (33)	v23 (27)	18 (21)	30-day MACE
Yun KH, et al. (7)	ARMYDA-ACS, 2008	225	220	64 (10)	63 (11)	136 (60)	137 (62)	75 (33)	65 (30)	NA	NA	14 (6)	18(8)	periprocedural myocardial infarction
Veselka J, et al. (8)	ARMYDA-ACS, 2009	100	100	68 (11)	64 (10)	54 (54)	79 (79)	26 (26)	25 (25)	40 (40)	33 (33)	0(0)	0(0)	periprocedural myocardial infarction
Briguori C, et al. (9)	NAPLES II, 2009	338	330	64 (9)	65 (10)	266 (78)	263 (80)	130 (39)	121 (37)	NA	NA	43 (13)	46 (14)	periprocedural myocardial infarction

DM = diabetes mellitus; MACE = major adverse cardiac events; GPI = glycoprotein IIb/IIIa inhibitor.

Figure 2. Odds ratios of periprocedural myocardial infarction associated with statins pretreatment versus placebo in patients undergoing percutaneous coronary intervention. The size of the data marker is proportional to the weight of the individual studies, measured as the inverse of the variance in the study by the Mantel-Haenszel procedure.

Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, . Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004;110:674–8.

 PubMed Web of Science ®Google Scholar

Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, . Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004;25:1822–8.

 PubMed Web of Science ®Google Scholar

Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, . Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272–8.

 PubMed Web of Science ®Google Scholar

Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, . The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2008 Aug 13 (Epub ahead of print).

 Google Scholar

Veselka J, Zemánek D, Hájek P, Malý M, Adlová R, Martinkovicová L, . Effect of two-day atorvastatin pre-treatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. Am J Cardiol. 2009;104:630–3.

 Google Scholar

Briguori C. NAPLES (Novel Approaches for Preventing or Limiting Event Study) II Trial: Impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. Presented at 58th annual scientific session of American College of Cardiology 2009 in Orlando, USA on 30 March 2009. Available at: http://assets.cardiosource.com/NAPLESII_Briguori.ppt. accessed on April 30th 2009.

 Google Scholar